Substantial attention has been paid to the global epidemic of diabetes among adults, but much less data are available for adolescents. Given the recent endorsement by the American Diabetes Association of glycated hemoglobin (HbA~1c~) for diabetes screening ([@B1]), a pilot HbA~1c~ screening program was implemented in adolescent blood donors by Carter BloodCare, the largest independent blood program in Texas.

HbA~1c~ was measured in 14,850 donors 16--19 years old during school blood drives conducted between 1 September 2011 and 30 April 2012. All donors gave informed consent. The main study measures were the prevalence of HbA~1c~ levels in the prediabetes range (5.7--6.4%; 39--46 mmol/mol) and in the diabetes range (≥6.5%; ≥48 mmol/mol), with further stratification by sex, race/ethnicity, and sociodemographic characteristics.

The cohort included 48.7% girls, 54.7% whites, 3.5% blacks, 24.6% Hispanics, 2.3% Asians, and 15% participants of other/unknown race/ethnicity. [Table 1](#T1){ref-type="table"} presents cohort characteristics stratified by HbA~1c~ category. The HbA~1c~ level was above the diabetes threshold in 94 donors (0.6%), and in the prediabetes range in 1,479 donors (10%).
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There were no significant age differences across HbA~1c~ categories (*P*~trend~ = 0.52), but a larger proportion of boys versus girls (16.5 vs. 5.0%, *P* \< 0.001) had HbA~1c~ levels ≥5.7% (including both the prediabetic and the diabetic range). There were also marked differences in the prevalence of HbA~1c~ levels ≥5.7% across race/ethnic groups, with over-representation of blacks and Asians in the elevated HbA~1c~ groups ([Table 1](#T1){ref-type="table"}). The HbA~1c~ level was ≥5.7% in 53.4% of blacks, 20.9% of Asians, 10.7% of Hispanics, and 7.5% of whites (*P* \< 0.001 for whites vs. every other race/ethnic group). In analyses stratified by sex and race/ethnicity, boys remained more likely than girls to have an HbA~1c~ level ≥5.7% within each race/ethnicity group (*P* \< 0.001 for each). In analyses of cardiovascular risk factors stratified by HbA~1c~ categories, higher total cholesterol levels and diastolic blood pressure were observed across categories of increasing HbA~1c~ ([Table 1](#T1){ref-type="table"}). Although secure online access to test results was provided to all donors, only 11% retrieved their HbA~1c~ results.

Limitations of this study include the absence of repeat/confirmatory testing for those with abnormal HbA~1c~, and the fact that HbA~1c~ thresholds established for adults have lower sensitivity for the detection of prediabetes and diabetes in adolescents ([@B2]), likely leading to an underestimation of the prevalence of these conditions in our cohort. However, the overall prevalence of HbA~1c~ levels of 5.7--6.4% in our study was comparable to the prevalence of prediabetes by fasting glucose and/or oral glucose tolerance testing in 16- to 19-year-old participants in the National Health and Nutrition Examination Survey 2005--2006 ([@B3]). The prevalence of HbA~1c~ levels ≥6.5% in our cohort was almost twofold higher than the estimated prevalence of diagnosed diabetes in U.S. youth ([@B4]), possibly reflecting a high prevalence of undiagnosed diabetes.

This pilot program demonstrates the feasibility of leveraging the community blood donation program as a unique and highly efficient portal for early health screening, with potential for public health intervention. With increased HbA~1c~ levels in U.S. adolescents and young adults recently associated with a higher risk of premature (\<55 years of age) death ([@B5]), early screening and intervention is more important than ever.
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